Last-Resort drug opens for advanced colon cancer patients
NCT ID NCT06195514
First seen Feb 01, 2026 · Last updated May 17, 2026 · Updated 17 times
Summary
This program offers an unapproved drug, fruquintinib, to adults with metastatic colorectal cancer who have no other treatment options left. It is for compassionate use when standard therapies have failed and clinical trials are not possible. The goal is to provide access until the drug is commercially available or no longer helps.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.